AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 57.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 654,504 shares of the medical device company's stock after selling 889,392 shares during the quarter. Wellington Management Group LLP owned approximately 1.34% of AtriCure worth $20,002,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Heck Capital Advisors LLC bought a new stake in shares of AtriCure in the 4th quarter worth about $60,000. Venturi Wealth Management LLC lifted its stake in AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after acquiring an additional 2,100 shares during the period. KBC Group NV lifted its stake in shares of AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after purchasing an additional 932 shares during the period. R Squared Ltd acquired a new stake in AtriCure in the fourth quarter valued at approximately $89,000. Finally, AlphaQuest LLC increased its stake in shares of AtriCure by 855.1% during the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock worth $155,000 after purchasing an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

ATRC has been the subject of several analyst reports. Piper Sandler upped their target price on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Oppenheimer upped their price objective on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Stifel Nicolaus increased their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. BTIG Research reissued a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Finally, Needham & Company LLC restated a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $49.44.

AtriCure Price Performance

AtriCure stock traded up $0.43 during midday trading on Friday, reaching $32.07. The company's stock had a trading volume of 331,646 shares, compared to its average volume of 667,282. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The stock's 50 day simple moving average is $36.01 and its 200 day simple moving average is $34.27. The firm has a market capitalization of $1.57 billion, a PE ratio of -33.76 and a beta of 1.65.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.